-+ 0.00%
-+ 0.00%
-+ 0.00%

Why Belite Bio shares are falling today

Barchart·11/20/2026 12:10:12
Listen to the news

BLTE Cover Image

What happened?

Shares of Belite Bio fell 14.5% in the afternoon session after the company announced that the U.S. Food and Drug Administration (FDA) extended the review period for the New Drug Application (NDA) for tinlarebant for the treatment of Stargardt disease type 1 by three months. 

The three-month review extension may have weighed on shares by delaying the decision on tinlarebant and prolonging uncertainty for investors. Under the revised timeline, the extended Prescription Drug User Fee Act (PDUFA) action date is May 12, 2027, giving the FDA additional time to review information provided in support of the NDA. 

If no major deficiencies are identified during the ongoing review, the agency plans to communicate proposed labeling requests and any anticipated postmarketing requirement requests, if necessary, by April 12, 2027.

The shares were trading at $129.50, down 14.5% from the previous close.

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.